EDAP to Distribute Lumenis Urological Lasers in France
June 24 2010 - 9:00AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that it has signed an exclusive
agreement with Lumenis, GmbH, to distribute Lumenis urological
Holmium/Nd:YAG lasers in France, starting June 2010.
This exclusive distribution agreement will allow EDAP to broaden
its products portfolio by offering urologists a new and high-end
therapeutic option to their existing tools. Lumenis lasers enable
precise minimally invasive treatment for a wide variety of urologic
conditions such as benign prostatic hyperplasia (BPH) and bladder,
urethral and kidney stones. With its strong knowledge of the French
urology market and its close relationships with French urologists,
EDAP is well positioned to strengthen its leadership in stone
management and urology with the addition of Lumenis' high-end
technology lasers.
Marc Oczachowski, CEO, commented, "I am very enthusiastic about
adding Lumenis lasers, recognized as top ranked urology lasers, to
our product offering in France. For years, EDAP has proven its
leadership and track record in selling urological medical devices
in France. In addition to representing a new revenue opportunity,
the distribution of Lumenis' lasers in France will reinforce EDAP's
presence in the urological field by further positioning us as one
of the major players offering a wide range of minimally-invasive
technologies to patients with urological conditions."
Lloyd Diamond, President EMEA, from Lumenis, added, "We are
pleased to enter into this distribution agreement with
EDAP. The French urology market is important to Lumenis and we
now have the best partner to develop and support it. The
combination of EDAP and Lumenis products provides a comprehensive
solution to many of the urologists' stone and prostate needs."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA.
The Company also is developing this technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy
(ESWL). For more information on the company, please visit
http://www.edap-tms.com, http://www.hifu-planet.com.
About Lumenis
Lumenis, one of the world's largest medical laser
companies, is a global developer, manufacturer and distributor
of laser and light-based devices for surgical, ophthalmic and
aesthetic applications, with more than 800 employees worldwide.
Lumenis has nearly 250 patents, over 75 FDA clearances, an
installed base of over 80,000 systems and presence in over 100
countries. Lumenis endeavors to bring the finest state of the
art technology products to the market, fulfilling the highest
standards of excellence, quality and reliability, delivering
premium value and service to its customers. The name Lumenis
is derived from the Latin words meaning "Light of Life"
highlighting the light, which is the basis of our technologies used
to enhance life. For more information about Lumenis and its
products, please go to: http://www.lumenis.com.
CONTACT: EDAP TMS SA
Investor Relations/Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com
Lumenis
Michelle Maydan, Director of Corporate Communications
1-866-569-0597
+972-4-959-9004
mmaydan@lumenis.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024